HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

888.076

+9.2871.06%

Number of Gainers:11

Number of Losers:6

Number of Flat:- -

PE:- -

High:891.617

Open:876.263

Low:869.207

Close:878.789

Volume:269.27M

Turnover:2.12B

Market Cap:600.24B

Float Cap:496.87B

Loading ...

China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Ascletis Pharma Inc. - Board of Directors Does not Recommend Payment of Any Dividend in Respect of Hy

THOMSON REUTERS

Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million

Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million

THOMSON REUTERS

Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug

MT Newswires Live

CSPC Pharma Begins Trial for Weight Management Drug in China

MT Newswires Live

China's C.banner Returns to Profit on Lower Expenses

CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff

CSPC Pharma Wins China NMPA Clearance to Start Phase 1 Trial of Syh2092 Obesity Drug

CSPC Pharmaceutical - Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in China

THOMSON REUTERS

Shanghai Junshi Biosciences Says Shanghai Tanying Investment Plans Reduction Stake

MT Newswires Live

SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC

Sino Biopharma Licenses HER2 ADC Tqb2102 to Cipla for India, South Africa, Other Emerging Markets in Deal Worth up to USD 123 Million

Sino Biopharmaceutical - Cipla Granted Exclusive License for Tqb2102 in India, South Africa and Five Markets

THOMSON REUTERS

Sino Biopharmaceutical - Group Eligible for up to $123 Mln in Milestone Payments and Tiered Double-Digit Royalties

THOMSON REUTERS

Jefferies Adjusts BYD Electronic (International)'s Price Target to HK$25 From HK$29, Keeps at Hold

MT Newswires Live

Cipla and SBP Group Sign Exclusive Licensing Agreement for HER2 Bispecific Antibody-Drug Conjugate

China's AustAsia Swings to Profit in H1, Aided by Lower Feed Costs and Higher Beef Prices

Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK1515/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":888.07635,"timestamp":1789373282104,"preClose":878.7892,"halted":0,"volume":269268704,"delay":0,"changeRate":0.010568,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":9.28717,"latestTime":"09-14 16:00:00","open":876.263,"high":891.617,"low":869.2073,"amount":2123131721,"amplitude":0.025501,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"pbRate":1.318473,"peRate":17.086203,"turnoverRate":0.003534,"increases":11,"decrements":6,"flats":0,"marketCap":600236234944,"floatMarketCap":496865354048},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":891.617,"amplitude":0.025501,"preClose":878.7892,"low":869.2073,"pbRate":"1.318473","latestPrice":888.07635,"volume":269268704,"delay":0,"open":876.263,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":942.123,"twentyDayClose":915.795,"sixtyDayClose":842.862,"secType":"PLATE","market":"HK","turnoverRate":0.003534,"peRate":17.086203,"marketCap":600236234944,"floatMarketCap":496865354048,"timestamp":1789373282104,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":11,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663966006","title":"China's Ascletis Pharma H1 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2663966006","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663966006?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:31","pubTimestamp":1788183111,"startTime":"0","endTime":"0","summary":"China's Ascletis Pharma H1 net loss widens on higher R&D costsOverviewChina biopharma developer's interim net loss widened 263% yr/yr to RMB319.7 mlnTotal income for the period fell 49% yr/yrR&D expen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK4551","BNTX","BK1161","BK4548","01672","01228","BK4535","BK4585","BK4588","BK4568","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123847780","title":"Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1123847780","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123847780?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:28","pubTimestamp":1788182898,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has unveiled its financial results for the six months ended June 30, 2026. The company recorded total revenue of RMB 52.979 million, representing a year-on-year decrease of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","01477","01672","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005700","title":"Ascletis Pharma Inc. - Board of Directors Does not Recommend Payment of Any Dividend in Respect of Hy","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663005700?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:16","pubTimestamp":1788182176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663100571","title":"Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663100571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663100571?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:15","pubTimestamp":1788182109,"startTime":"0","endTime":"0","summary":"Ascletis Pharma FY26 H1 net loss more than doubled to RMB 319.67 million; total income falls 48.9% to RMB 52.98 millionAscletis Pharma posted a net loss of RMB 319.67 million, more than tripling year-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL7N2P2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663800579","title":"Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663800579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663800579?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:15","pubTimestamp":1788182101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nPLX1DNJ6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003065","title":"Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003065","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003065?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:47","pubTimestamp":1788180431,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  unit Chia Tai Tianqing Pharmaceutical Group entered into an exclusive license and supply agreement with Cipla for cancer drug TQB2102.The group will grant Cipla an exclusive licence to develop and commercialize TQB2102 in India, South Africa, and five other emerging markets, according to a Monday Hong Kong bourse filing.Cipla will be responsible for local clinical development, regulatory activities, and commercialization, while Chia Tai Tianqing Pharmaceutical will continue to manufacture and supply the drug.The group will receive an upfront payment, and is eligible for potential development, regulatory, and sales milestone payments of up to $123 million, as well as tiered double-digit royalties.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","BK1515","IE00BZ08YR35.GBP","BK1589","IE00BZ08YT58.USD","BK1191","HK0000165453.HKD","IE00BZ08YS42.EUR","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003385","title":"CSPC Pharma Begins Trial for Weight Management Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003385?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:22","pubTimestamp":1788178969,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) officially began a phase I clinical trial of the SYH2092 injection at the first center in China.The drug has been developed for weight management in adult patients with obesity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B5MMRT66.SGD","LU0501845795.SGD","LU0326950275.SGD","LU1226287875.USD","HK0000165453.HKD","IE00BZ08YT58.USD","IE0008369823.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","01093","LU0140636845.USD","LU0067412154.USD","BK1191","BK1515","LU1226288170.HKD","LU1226287792.SGD","LU2039709279.SGD","LU1152091168.USD","LU1951186391.HKD","LU1226288253.USD","KURE","LU1328277881.USD","LU0880133367.SGD","LU1813983027.USD","LU1960683339.HKD","IE0008368742.USD","SG9999004220.SGD","LU1993786604.SGD","IE00B543WZ88.USD","LU0315179316.USD","IE00B031HY20.USD","LU1226287529.USD","LU1008478684.HKD","LU1807302812.USD","LU0314109678.HKD","LU0072913022.USD","BK1521","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663500821","title":"China's C.banner Returns to Profit on Lower Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663500821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663500821?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:11","pubTimestamp":1788178299,"startTime":"0","endTime":"0","summary":"China's C.banner returns to profit on lower expensesOverviewChina footwear retailer's half-year revenue declined yr/yrCompany returned to profit for the period, posting RMB 6.8 mlnBasic EPS improved t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1168","BK1191","BK1227","BK1606","00844","00570","BK1515","01028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178504231","title":"CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff","url":"https://stock-news.laohu8.com/highlight/detail?id=1178504231","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178504231?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177626,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) has announced the official initiation of the first clinical trial site in China for its Phase 1 study of the SYH2092 injection, targeting weight management in adults who are...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","BK1515","LU1226287529.USD","IBBQ","LU1813983027.USD","LU1993786604.SGD","IE00B031HY20.USD","LU1951186391.HKD","IE0008369823.USD","IE00BZ08YT58.USD","PSYK","LU0067412154.USD","LU1226287792.SGD","HK0000165453.HKD","BK1521","KURE","LU1807302812.USD","IE00B543WZ88.USD","LU0326950275.SGD","SG9999004220.SGD","LU0072913022.USD","MDTX","BMED","LU1328277881.USD","IE0008368742.USD","LU0314109678.HKD","LU0315179316.USD","01093","LU1008478684.HKD","LU0140636845.USD","LU1152091754.HKD","LU1226287875.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU2039709279.SGD","IE00BZ08YR35.GBP","BK1191","LU0880133367.SGD","IBBJ","LU1960683339.HKD","LU1226288253.USD","IE00BZ08YS42.EUR","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008868","title":"CSPC Pharma Wins China NMPA Clearance to Start Phase 1 Trial of Syh2092 Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008868","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008868?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:53","pubTimestamp":1788177190,"startTime":"0","endTime":"0","summary":"CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drugCSPC received China NMPA clearance in August 2026 to start clinical trials of SYH2092 for weight management in overw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLnjzPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","IE00BZ08YT58.USD","LU1226287792.SGD","IE00BZ08YR35.GBP","LU1226287875.USD","LU1226288170.HKD","LU0314109678.HKD","01093","LU0880133367.SGD","LU0067412154.USD","LU1993786604.SGD","LU0140636845.USD","LU1226288253.USD","BK1515","LU1152091168.USD","LU1807302812.USD","LU1008478684.HKD","LU1813983027.USD","LU0501845795.SGD","LU0326950275.SGD","LU1960683339.HKD","IE00B5MMRT66.SGD","KURE","LU0072913022.USD","IE00B543WZ88.USD","LU0315179316.USD","LU1152091754.HKD","LU1951186391.HKD","SG9999004220.SGD","BK1191","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","IE0008368742.USD","LU2039709279.SGD","LU1226287529.USD","LU1328277881.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663882008","title":"CSPC Pharmaceutical - Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2663882008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663882008?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:52","pubTimestamp":1788177157,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S098:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1152091168.USD","IE00BZ08YR35.GBP","BK1521","IE0008369823.USD","LU1993786604.SGD","BK1515","LU0326950275.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU1813983027.USD","LU1807302812.USD","LU1226287792.SGD","LU0067412154.USD","LU1226287529.USD","LU1951186391.HKD","LU1226288170.HKD","LU1152091754.HKD","IE0008368742.USD","LU0315179316.USD","LU1226288253.USD","SG9999004220.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","BK1191","KURE","LU1960683339.HKD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU0072913022.USD","LU0140636845.USD","01093","LU0880133367.SGD","LU1226287875.USD","LU1328277881.USD","LU2039709279.SGD","IE00B031HY20.USD","LU0501845795.SGD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070801","title":"Shanghai Junshi Biosciences Says Shanghai Tanying Investment Plans Reduction Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070801","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070801?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:28","pubTimestamp":1788175685,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  said Shanghai Tanying Investment Partnership is planning to reduce its shareholding in the company by up to over 20.5 million shares.Shanghai Tanying Investment Partnership holds 38.9 million China-listed shares in the company, according to a Monday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","688180","BK1583","BK0239","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184588789","title":"SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=1184588789","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184588789?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:54","pubTimestamp":1788173661,"startTime":"0","endTime":"0","summary":"SBP Group (01177) has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has entered into an exclusive licensing and supply agreement with Cipla Limited for the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","HK0000165453.HKD","BK1191","BK1515","IE00BZ08YR35.GBP","BK1589","IE00BZ08YT58.USD","BK1521","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663843072","title":"Sino Biopharma Licenses HER2 ADC Tqb2102 to Cipla for India, South Africa, Other Emerging Markets in Deal Worth up to USD 123 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663843072","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663843072?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:40","pubTimestamp":1788172833,"startTime":"0","endTime":"0","summary":"Sino Biopharma licenses HER2 ADC TQB2102 to Cipla for India, South Africa, other emerging markets in deal worth up to USD 123 millionSino Biopharmaceutical unit Chia Tai Tianqing signed an exclusive l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL8ylZt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","IE00BZ08YT58.USD","01177","BK1191","BK1515","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074047","title":"Sino Biopharmaceutical - Cipla Granted Exclusive License for Tqb2102 in India, South Africa and Five Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:39","pubTimestamp":1788172791,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R02R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","BK1521","BK1589","01177","IE00BZ08YT58.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074024","title":"Sino Biopharmaceutical - Group Eligible for up to $123 Mln in Milestone Payments and Tiered Double-Digit Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074024?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:39","pubTimestamp":1788172791,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R02R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","BK1515","BK1589","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1191","01177","IE00BZ08YS42.EUR","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663639074","title":"Jefferies Adjusts BYD Electronic (International)'s Price Target to HK$25 From HK$29, Keeps at Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2663639074","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663639074?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:19","pubTimestamp":1788171577,"startTime":"0","endTime":"0","summary":"Jefferies Adjusts BYD Electronic (International)'s Price Target to HK$25 From HK$29, Keeps at Hold","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00285","LU0348766576.USD","LU0348767384.USD","BK1167","BK1589","BK1582","BK1515","BK1504","BK1540","BK1580","LU0274383008.USD","BK1149","BK1607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663107455","title":"Cipla and SBP Group Sign Exclusive Licensing Agreement for HER2 Bispecific Antibody-Drug Conjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2663107455","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663107455?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:16","pubTimestamp":1788171379,"startTime":"0","endTime":"0","summary":"BRIEF-Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug ConjugateAug 31 (Reuters)-Cipla LtdCIPL.NS:CO AND SBP GROUP SIGN EXCLUSIVE LICENSING AGREEMENT FOR HER2 B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1191","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","01177","IE00BZ08YS42.EUR","BK1521","BK1515","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074834","title":"China's AustAsia Swings to Profit in H1, Aided by Lower Feed Costs and Higher Beef Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074834?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:10","pubTimestamp":1788171031,"startTime":"0","endTime":"0","summary":"China's AustAsia swings to profit in H1, aided by lower feed costs and higher beef pricesOverviewChina dairy and beef producer's revenue rose 1.6% yr/yr for six months ended JuneNet income attributabl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0086","BK0183","600085","BK0113","BK1191","BK1515","BK0239","02425","LU1688375341.USD","BK0188","BK0012","BK1583","BK1237","BK1606","BK0028","BK0097","01666","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663437071","title":"Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2663437071","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663437071?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:00","pubTimestamp":1788170409,"startTime":"0","endTime":"0","summary":"Hong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product salesOverviewHong Kong pharma maker's interim revenue grew 14.6% yr/yr for six months ended June 2026Net income attributable t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570","BK1606","00950","BK1583","BK1515","BK1574","06622","BK1191","BK1587","01477"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":191,"code":"91000000","status":"200"}]}}